Efficacy of R-CDOP regimen in the treatment of diffuse large B-cell lymphoma and its influence on immune function and prognosis
Objective To investigate the efficacy,immune function,and prognosis of R-CDOP in the treatment of diffuse large B-cell lymphoma.Methods Fifty-two patients with diffuse large B-cell lymphoma who were treated in Taizhou Central Hospital(Taizhou University Hospital)from October 2017 to June 2020 and followed up until July 2022 were selected as the study objects.According to random number table method,they were divided into observation group(treated with R-CDOP regimen)and control group(treated with R-CHOP regimen),with 26 cases each.Response rate,immune function(CD3+,CD4+,CD8+),toxicity,two-year survival rate and survival time of two groups were compared.Results The objective effective rate and complete remission rate of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).After chemotherapy,CD3+and CD4+in two groups were lower than before chemotherapy,and those of the observation group were higher than those of the control group;CD8+in both groups was higher than before chemotherapy,and that of the observation group was lower than that of the control group and the differences were statistically significant(P<0.05).The total incidence of side effects in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).The 2-year survival rate and survival time of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).Conclusion R-CDOP is effective in the treatment of diffuse large B-cell lymphoma,which is beneficial to reduce the influence on immune function and has high safety.
Doxorubicin liposomeDiffuse large B-cell lymphomaImmune functionToxic side effectsPrognosis